medigraphic.com
Instituto Nacional de Salud Pública

2014, Number 5

<< Back Next >>

salud publica mex 2014; 56 (5)

Incidencia, mortalidad y supervivencia al cáncer de próstata en Cali, Colombia, 1962-2011

Restrepo JA, Bravo LE, García-Perdomo HA, García LE, Collazos P, Carbonell J

Language: Spanish
References: 24
Page: 440-447
PDF size: 246.35 Kb.


ABSTRACT

Objective. To analyze the trend in prostate cancer survival, incidence and mortality rates in Cali, Colombia from 1962 to 2011. Materials and methods. Based on the Cancer Registry of Cali, Colombia and the mortality registry of the City’s Public Health Secretary, incidence, mortality age-standardized rates and relative survival were calculated during 1962-2011. Results. Prostate cancer incidence rates increased sharply between 1986 and 2002 (APC: 6.21%) and then leveled off. Mortality diminished in 1997 in men older than 70 years-old while in men aged 50-69 years declined since 1981. The 5-year-relative-survival was 69.8% (CI95% 67.5-72.0) and it was significantly associated with age, quinquennial period of diagnosis and socioeconomic strata. Conclusion. The increase in incidence rates of prostate cancer in time coincides with the implementation of the PSA in Cali. There is evidence of improvement in prostate cancer survival, and decreased prostate cancer mortality.


REFERENCES

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer 2010; 127(12):2893-2917.

  2. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. European Urology 2012;61:1079-1092.

  3. Baquet CR, Horm JW, Gibbs T, Greenwald P. Socioeconomic factors and cancer incidence among blacks and whites. J Natl Cancer Inst 1991;83:551-557.

  4. Stanford JL, Ostrander EA. Familial prostate cancer. Epidemiol Rev 2001;23(1):19-23.

  5. Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Tjønneland A, et al. Animal foods, protein, calcium and prostate cancer risk: the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2008;98:1574-1581.

  6. Crowe FL, Key TJ, Appleby PN, Travis RC, Overvad K, Jakobsen MU, et al. Dietary fat intake and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Am J Clin Nutr 2008;87(5):1405-1413.

  7. Brawley OW. Trends in prostate cancer in the United States. J Natl Cancer Inst Monogr 2012;2012(45):152-156.

  8. Bravo LE, Collazos T, Collazos P, García LS, Correa P. Trends of cancer incidence and mortality in Cali, Colombia. 50 years experience. Colomb Med 2012;43(4):246-255.

  9. Rosa RM, Alberto IC. Universal health care for Colombians 10 years after Law 100: challenges and opportunities. Health Policy 2004;68(2):129-142.

  10. Colombia. Departamento Administrativo Nacional de Estadística. Proyecciones de población 2005-2020. Bogotá: Departamento Administrativo Nacional de Estadística, 2010.

  11. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317(15):909-916.

  12. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324(17):1156-1161.

  13. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273(7):548-552.

  14. Larrañaga N, Galceran J, Ardanaz E, Franch P, Navarro C, Sánchez MJ, et al. Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: impact on mortality. Ann Oncol 2010;21(suppl 3):iii83-89.

  15. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, et al. Early detection of prostate cancer: AUA Guideline. J Urol 2013;190(2):419-426.

  16. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev 2013;31(1):CD004720.

  17. Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D, et al. Prostate cancer mortality in the USA and UK in 1974–2004 an ecological study. Lancet Oncol 2008;9(5):445-452.

  18. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, et al. Cancer surveillance series: interpreting trends in prostate cancer–part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999;91(12):1017-1024.

  19. Etzioni R, Legler JM, Feuer EJ, Merrill RM, Cronin KA, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer–part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 1999;91(12):1033-1039.

  20. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004;172:1297-1301.

  21. Moyer VA, LeFevre ML, Siu AL, Baumann LC, Bibbins-Domingo K, Curry SJ, et al. Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals Intern Med 2012;157(2):120-134.

  22. Coleman M, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population based study (Concord). The Lancet Oncology 2008;9(8):730-756.

  23. Parkin DM, Ferlay J, Curado MP, Bray F, Edwards B, Shin HR, et al. Fifty years of cancer incidence: CI5 I-IX. Int J Cancer 2010;127(12):2918-2927.

  24. Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, et al. Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J 2012;18(1):1-8.




2020     |     www.medigraphic.com